Numerous emerging Trop2-targeted modalities, such as bispecific antibodies/ADCs and CAR-T cell therapies, are undergoing active investigation in the early clinical phase, with some showing the potential to revolutionize the care of Trop2-positive cancers. This evidence concerns the gene TACSTD2 and cancer.